Clinical Trial Update: Lower But More Frequent Dose Rituximab to Treat Chronic Lymphocytic Leukemia [Phase 1]

View source ↗

Summary

A Phase 1 trial evaluated a lower, more frequent dosing regimen of rituximab for refractory chronic lymphocytic leukemia, with the study status reported as comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Refractory Chronic Lymphocytic Leukemia | Phase 1 | Status: COMPLETED